Hormone Refractory Prostate Cancer (HRPCA) Market Report Analysis from 2014 - 2022
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global Hormone Refractory Prostate Cancer (HRPCA) market is poised to witness an unprecedented growth.
View full press release